The estimated Net Worth of Thomas Ryll is at least 4.21 百万$ dollars as of 24 February 2020. Thomas Ryll owns over 16,790 units of Immunogen stock worth over 2,362,494$ and over the last 7 years he sold IMGN stock worth over 277,365$. In addition, he makes 1,566,750$ as Vice President、 Technical Operations at Immunogen.
Sign up
Thomas Ryll IMGN stock SEC Form 4 insiders trading
Thomas has made over 3 trades of the Immunogen stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 16,790 units of IMGN stock worth 83,782$ on 24 February 2020.
The largest trade he's ever made was selling 16,790 units of Immunogen stock on 24 February 2020 worth over 83,782$. On average, Thomas trades about 3,651 units every 67 days since 2018. As of 24 February 2020 he still owns at least 75,624 units of Immunogen stock.
You can see the complete history of Thomas Ryll stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Ryll biography
Dr. Thomas Ryll Ph.D. serves as Vice President, Technical Operations of the Company. serves as Vice President, Technical Operations of the Company. He joined ImmunoGen in 2015, Prior to that he served as Vice President, Process and Analytical Development, from his date of hire to 2017. Prior to joining ImmunoGen, he spent almost nine years at Biogen Inc. (formerly known as Biogen Idec Inc.), a biopharmaceutical company, in roles of increasing responsibility in the area of cell line culture development, including Senior Director in Biogen’s technical development department. Dr. Ryll holds a PhD in biotechnology and biochemistry from the Technical University of Braunschweig, Germany, and completed his post-doctoral work at the Society for Biotechnology Research (now the Helmholtz Center for Infection Research) in Germany.
What is the salary of Thomas Ryll?
As the Vice President、 Technical Operations of Immunogen, the total compensation of Thomas Ryll at Immunogen is 1,566,750$. There are 2 executives at Immunogen getting paid more, with Mark Enyedy having the highest compensation of 3,917,560$.
How old is Thomas Ryll?
Thomas Ryll is 58, he's been the Vice President、 Technical Operations of Immunogen since 2017. There are 8 older and 8 younger executives at Immunogen. The oldest executive at Immunogen, Inc. is Richard Wallace, 68, who is the Independent Director.
What's Thomas Ryll's mailing address?
Thomas's mailing address filed with the SEC is C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM, MA, 02451.
Insiders trading at Immunogen
Over the last 21 years, insiders at Immunogen have traded over 72,947,831$ worth of Immunogen stock and bought 303,125 units worth 974,603$ . The most active insiders traders include Biochem Incshire Pharmaceut...、Capital, L.P.Morton Holding...、Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of 2,554,057$. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth 448,294$.
What does Immunogen do?
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
What does Immunogen's logo look like?
Complete history of Thomas Ryll stock trades at Immunogen
Immunogen executives and stock owners
Immunogen executives and other stock owners filed with the SEC include:
-
Mark Enyedy,
President, Chief Executive Officer, Director -
Anna Berkenblit,
Senior Vice President and Chief Medical Officer -
Thomas Ryll,
Vice President, Technical Operations -
Mark Joseph Enyedy,
Pres, CEO & Director -
Dr. Anna Berkenblit,
Sr. VP & Chief Medical Officer -
Dr. Theresa G. Wingrove,
Sr. VP of Regulatory Affairs & Quality -
Stacy A. Coen,
Sr. VP & Chief Bus. Officer -
Stephen McCluski,
Independent Chairman of the Board -
Kristine Peterson,
Independent Director -
Richard Wallace,
Independent Director -
Dean Mitchell,
Independent Director -
Mark Goldberg,
Independent Director -
Stuart Arbuckle,
Independent Director -
Theresa Wingrove,
Senior Vice President - Regulatory Affairs and Quality -
Stacy Coen,
Senior Vice President and Chief Business Officer -
Susan Altschuller,
Chief Financial Officer, Senior Vice President -
Kristen Harrington-Smith,
Sr. VP & Chief Commercial Officer -
Audrey Bergan,
VP & Chief HR Officer -
Courtney O'Konek,
Sr. Director of Corp. Communications & Investor Relations -
Dr. Thomas Ryll,
Sr. VP of Technical Operations -
Renee Lentini,
VP of Fin., Principal Accounting Officer & Corp. Controller -
Peter J. Williams,
VP, Business Development -
John Lambert,
Senior Vice President -
Joseph J Villafranca,
Director -
Richard J. Gregory,
Executive VP & CSO -
Charles Q Morris,
Executive VP & CDO -
Daniel M Junius,
Chief Financial Officer -
David Brannon Johnston,
Chief Financial Officer -
Ellie Harrison,
VP & Chief HR Officer -
Howard H Pien,
Director -
Lauren White,
SVP, CFO AND PFO -
David G Foster,
V.P.-Fin., Prin. Acctg. Off. -
Blaine H. Mc Kee,
EVP & Chief Business Officer -
Nicole Onetto,
Director -
Craig Barrows,
Executive VP, General Counsel -
Sandra Poole,
Senior VP, Tech Operations -
Mark B Skaletsky,
Director -
Gregory D Perry,
Chief Financial Officer -
James J O'leary,
Vice President -
Biochem Incshire Pharmaceut...,
-
Karleen Marie Oberton,
Senior Corporate Controller -
Virginia Lavery,
VP and Senior Controller -
Gregg Beloff,
Vice President and CFO -
Christopher U Missling,
Chief Financial Officer -
Capital, L.P.Morton Holding...,
-
David Warren Carter,
Director -
Mitchel Sayare,
Chief Executive Officer -
John Tagliamonte,
VP, Business Development -
Stuart Feiner,
Director -
Pauline Jen Ryan,
VP Business Development -
Walter Blattler,
Executive Vice President -
Isabel Kalofonos,
SVP & CHIEF COMMERCIAL OFFICER -
Tracey L Mc Cain,
Director -
Michael Vasconcelles,
EVP R&D & MEDICAL AFFAIRS -
Daniel Char,
SVP & CHIEF LEGAL OFFICER -
Helen M. Thackray,
Director -
Kristen Harrington Smith,
SVP & CHIEF COMMERCIAL OFFICER -
Renee Lentini,
VP & PRIN ACCTG OFFICER